EvaluatePharma - Eli Lilly - Worldwide

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Eli Lilly (LLY), an Indiana based global provider of pharmaceutical and animal health products.
Listed or Private Company	Listed
Company Classification	Global Majors
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
8/17/2010	17 Aug: Company terminates two phase III trials of semagacestat in 2,600 Alzheimer's patients after the gamma secretase inhibitor was shown in a preliminary analysis to significantly worsen clinical measures of cognition and daily living activities compared to placebo; the drug was also associated with an increased risk of skin cancer. 17 Aug: FDA briefing documents released ahead of an advisory committee meeting on 19 Aug raises safety concerns over wider use of Cymbalta to treat chronic pain and questions the company's trial design and analysis.	40,072	-2.3%	-945

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Zyprexa	olanzapine	Anti-psychotics	4,761²	4,696³	-1%
2	Cymbalta	duloxetine hydrochloride	Anti-depressants	2,103⁴	2,697⁵	+28%
3	Humalog	insulin lispro	Anti-diabetics	1,475⁶	1,736⁷	+18%

Note: Shaded Cells⁸

RX Sales Chart

Eli Lilly	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals	16,936⁹	18,659¹⁰	+10%

Therapy Area Focus in 2008

Eli Lilly
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	417
Cardiovascular¹¹	21¹²
Central Nervous System¹³	8,346¹⁴
Endocrine¹⁵	3,416¹⁶
Genito-Urinary¹⁷	1,470
Musculoskeletal	1,854
Oncology & Immunomodulators¹⁸	2,872¹⁹
Systemic Anti-Infectives²⁰	206²¹
Other Rx & OTC Pharma	56

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Eli Lilly ²²	281

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON


	Product	Generic Name
Eli Lilly	A-001 (LY315920/S-5920)	varespladib
	A-002 (LY333013/S-3013)	varespladib methyl
	A-003	-
	Abegrin	etaracizumab
	Actos	pioglitazone hydrochloride
	Adcirca	tadalafil
	ADL5945	-
	Affinitak	aprinocarsen
	AIR Inhaled Insulin	insulin
	Alamifovir (MCC-478)	alamifovir
	Alimta	pemetrexed sodium
	Alzheimer Research Project	-
	Alzheimer's Diagnostic Research Project	-
	Alzheimer's Disease Research Project	-
	Alzheimer's Therapy Research Project	-
	AME-359	-
	AME-527	-
	Anti-Cancer Monoclonal Antibodies	-
	Anti-CD20 Antibody (AME-133v)	-
	Anti-CD40 MAb	teneliximab
	Anti-gp75/TRP-1 MAb	-
	Anti-NSCLC MAb	-
	Arxxant	ruboxistaurin mesylate
	Arzoxifene	arzoxifene
	AV965	-
	Axid	nizatidine
	Axid OS	nizatidine
	Axiron	testosterone
	AZP-01	-
	BAFF Ab	-
	Basal insulin	-
	BCR-ABL inhibitor	-
	BRCA-1	-
	Brevital	methohexital sodium
	Bydureon	exenatide
	Byetta	exenatide
	Cancer's Diagnostic Research Project	-
	Cancer's Therapy Research Project	-
	Capastat	capreomycin
	CDP-791	-
	Ceclor	cefaclor
	Cell Adhesion Molecule Antagonist	-
	Cesamet	nabilone
	Cialis	tadalafil
	Cinobac	cinoxacin
	CNS Disease Research Project	-
	Cordran	flurandrenolide
	CORT 108297	-
	CPZEN-45	-
	CRF R2 Agonist	-
	Cubicin	daptomycin
	Cymbalta	duloxetine hydrochloride
	Cynt	moxonidine
	Cystic Fibrosis Research Project	-
	Darvocet	acetaminophen & propoxyphene napsylate
	Darvon	propoxyphene hydrochloride
	Darvon-N	propoxyphene napsylate
	Decabid	indecainide hydrochloride
	Distalgesic	acetaminophen & propoxyphene hydrochloride
	Dobutrex	dobutamine hydrochloride
	DP-2514	-
	DP-3346	-
	Dynabac	dirithromycin
	E4G10	-
	EB10-MMAF	-
	Effient	prasugrel
	Eflucimibe	eflucimibe
	Eldisine	vindesine
	Eli Lilly/Neurosearch CNS Research Project	-
	Eli Lilly/Transition Diabetic Research Project	-
	Eli Lilly/Zydus Cardiovascular Research Program	-
	Eloxatin	oxaliplatin
	Enantyum	dexketoprofen trometamol
	Entereg/Entrareg	alvimopan
	Enzastaurin	enzastaurin
	Eraxis/Ecalta	anidulafungin
	Erbitux	cetuximab
	Ethyol	amifostine
	Evista	raloxifene hydrochloride
	Exenatide Nasal	exenatide
	Factor Xa inhibitor	-
	Fasidotril	fasidotril
	Forteo/Forsteo	teriparatide acetate
	Gastrin + DPP -IV Inhibitors	-
	GED-aPC	-
	Gemcitabine Prodrug	-
	Gemzar	gemcitabine hydrochloride
	GLP-1 PEG (LY2428757)	-
	Glucagon	glucagon hydrochloride
	G-protein Coupled Receptor Antagonist	-
	GRC 6211	-
	GT328	-
	HBR96	-
	Hexalen	altretamine
	hF4-3C5	-
	HGH	somatropin
	HNF-4 Modulators	-
	HUI77	-
	HUIV26	-
	Humalog	insulin lispro
	Humatrope	somatropin
	Humulin ReliOn	insulin (human)
	IC14	-
	IC776 (LFA-1 Antagonist)	-
	IC83 (Cell Cycle Checkpoint/DNA Repair Inhibitor)	-
	iGluR5 Antagonist	-
	IL-1 Beta Antibody	-
	IL-17 Ab	-
	IL-23 Antibody	-
	Iletin	insulin (porcine)
	Ilosone	erythromycin estolate
	IMC-1121B	ramucirumab
	IMC-11F8	necitumumab
	IMC-18F1	-
	IMC-20D7S	-
	IMC-3G3	olaratumab
	IMC-A12	cixutumumab
	IMC-D11	-
	IMC-EB10	-
	INCB28050	-
	INGAP-Peptide	-
	Inhaled Insulin	insulin
	Inhaled PTH	teriparatide acetate
	ISIS 345794	-
	ISIS-EIF4ERx	-
	JAK2 inhibitor	-
	Keflex	cephalexin
	Kefurox	cefuroxime sodium
	Kefzol	cefazolin sodium
	K-RAS	-
	Lasmiditan	lasmiditan
	LGD1268	-
	LGD1324	-
	Liprotamase	liprotamase
	Livalo	pitavastatin calcium
	Lorabid	loracarbef
	LP10152 (FGF-21)	-
	Lu AE58054	-
	LY-121019	cilofungin
	LY-156735	-
	LY2140023	-
	LY2157299	-
	LY2189265	dulaglutide
	LY2196044	-
	LY2216684	-
	LY2382770	-
	LY2393910	-
	LY2409021	-
	LY2452473	-
	LY2484595	-
	LY2523355 (K858)	litronesib
	LY2541546	-
	LY2584702	-
	LY2590443	-
	LY2599506	-
	LY2605541	-
	LY2606368	-
	LY2608204	-
	LY2624587	-
	LY2624803	-
	LY2780301	-
	LY2784544	-
	LY2787206	-
	LY2801653	-
	LY2811376	-
	LY2835219	-
	LY2875358	-
	LY2886721	-
	LY-295501	-
	LY300046-HCL	trovirdine
	LY-300502	bexlosteride
	LY-303870	lanepitant
	LY-307161	-
	LY-309887	-
	LY-315535	-
	LY-320236	izonsteride
	LY-334370	-
	LY354740	eglumetad
	LY-355703	cryptophycin 52
	LY377604	-
	LY450139	semagacestat
	LY451395	mibampator
	LY-466700	-
	LY500307	-
	LY517717	-
	LY544344	talaglumetad
	LY573636	tasisulam sodium
	LY674	-
	LY686017	-
	LY929	-
	LYWWW	-
	LYYYY	-
	MAG-131	-
	Mandol	cefmandole
	MAR531	-
	MBP8298	dirucotide
	MEDI-528	enokizumab
	Metabolic/Inflammatory Antisense Research Project	-
	mGluR3 Antagonist	-
	Moxam	moxalactam disodium
	Nalfon	fenoprofen calcium
	Naveglitazar (LY818)	naveglitazar
	Nebcin	tobramycin sulfate
	NERI IV	-
	Neuropilin MAb	-
	NeuTrexin	trimetrexate glucuronate
	NGX424	tezampanel
	NGX426	-
	Notch Inhibitor	-
	Novel Antibiotics	-
	NOXXON/Lilly Research Project	-
	Numax	motavizumab
	Ob protein analog	-
	Obesity Molecule	-
	Obesity Program	-
	Oncovin	vincristine
	Ontak	denileukin diftitox
	OpRA II	-
	Optro	haemoglobin
	Oraflex	benoxaprofen
	Oral Recombinant Human Growth Hormone	somatropin
	Oralin	insulin
	P1201-07	-
	Pagibaximab	pagibaximab
	PAI-1 Inhibitors (Anti-Cancer)	-
	PDE4 Inhibitors	-
	Permax	pergolide mesylate
	Phosphodiesterase Inhibtors	-
	Pindac	pinacidil
	Priligy	dapoxetine hydrochloride
	Prozac	fluoxetine hydrochloride
	Pruvanserin (EMD 281014)	pruvanserin
	PTH 1-34	teriparatide acetate
	R-848	resiquimod
	RAF + cKIT inhibitors	-
	RAF + HER inhibitors	-
	RAF + KDR inhibitors	-
	Ramvocid	oritavancin
	Recombinant glucagon	glucagon hydrochloride
	ReoPro	abciximab
	R-Fluoxetine	(R)-fluoxetine
	RNAi Oncology Research Project	-
	RON	-
	RON-8	-
	ROSE-010	-
	RXR Modulators	-
	Selective RAF inhibitors	-
	Seromycin	cycloserine
	SGX126	-
	SGX393	-
	Sivelestat	sivelestat sodium
	Solanezumab	solanezumab
	Strattera	atomoxetine hydrochloride
	Survivin ASO (LY2181308)	gataparsen sodium
	Symbyax	fluoxetine hydrochloride & olanzapine
	T64	lometrexol
	Talampanel	talampanide
	Tapazole	methimazole
	Targretin	bexarotene
	Tazidime	ceftazidime
	Tazofelone	tazofelone
	Teplizumab	teplizumab
	Transdermal Exenatide	exenatide
	TS-021	-
	TT-223	-
	TT-223 + EGF Analogue/E1-I.N.T	-
	TT-223 + GLP-1 Analogue/GLP1-I.N.T	-
	Tuberculosis Research Programme	-
	Tuberculosis Research Project	-
	Vancocin	vancomycin monohydrochloride
	Velbe/Velban	vinblastine
	ViaDerm-hPTH (1-34)	teriparatide acetate
	VML 670	-
	VX-950	telaprevir
	Xanomeline	xanomeline
	Xigris	drotrecogin alfa
	XR334 (Anti-Thrombotic PAI-1 Inhibitors)	-
	Yentreve/AriClaim	duloxetine hydrochloride
	Zosuquidar (LY-335979)	zosuquidar hydrochloride
	Zypadhera	olanzapine pamoate
	Zyprexa	olanzapine

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Eli Lilly's glimmers of light unlikely to bring brighter news (August 20, 2010)

Is Lilly in need of a transformational deal? (August 20, 2010)

Therapeutic focus - What are plan B options if A-beta Alzheimer's hypothesis is void? (August 19, 2010)

Will gamma secretase Alzheimer's class survive the fall of semagacestat? (August 18, 2010)

Therapeutic focus - Vectibix failure leaves few new options for head and neck cancer (August 16, 2010)

Displaying 5 out of a possible 26 unique stories.
Results Sorted By date
Display All Stories

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXX XXXXX XX XXX X.X. XXXXXXXXX X XXXXXXX XX XXXX, XXXXXX XX XXXXXX XXX XXXXXXX XXXXXX, XXXXXXXXX XXXXXX XX XXXXX XXXXXX. XXXXX XXXXXXX XXX X.X. XXXXXXXXX XX XXXXXXX, XXXXXX XX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX XXX XXXXXXXXX XXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXX XXXX XXXX XX XXXX, XXXXXXXXX XXXXXXX XXXXX XXXXXXXXX X XXXXXXX, XX $X.XXX XXXXXXX. X.X. XXXXXXX XXXXX XXX XXXX XXXX $X.XXX XXXXXXX, X X XXXXXXX XXXXXXXX XXXXXX XX XXXXXX XXX XXXXXXX XXXXXX, XXXXXXXXX XXXXXX XX XXXXX XXXXXX. XXXXXXX XXXXX XXXXXXX XXX X.X. XXXX $X.XXX XXXXXXX, X XX XXXXXXX XXXXXXXX XXXXXX XX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX XXX XXXXXXXXX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX, XX:
XXXXXXX XXXXX XX $X.XX XXXXXXX XXXXXXXXXXX XX XXXXXXX XX XXX XXXXXXXX XX XXXX.

XXXX XX:
XXXXXXX, XXX XXX-XXXXXXX XXXXXXX, XX X XXXXXXXXX XXX XXXXXXXXXXXXX, XXXXX XXXXX XX XXXXX XXXXXXXX XXXXXXXXXX XXXX XXXXXXX X XXXXXXXX, XXX XXXXXXX XXXXXXXXXXX. XXXXXXX XXXXX XX XXX X.X. XXXXXXXXX X XXXXXXX XX XXXX, XXXXXX XX XXXXX XXXXXX, XXXXXXXXX XXXXXX XX XXXXXX XXXXXX. XXXXX XXXXXXX XXX X.X. XXXXXXXXX X XXXXXXX, XXXXXX XX XXXXXXXXX XXXXXX XXX XX X XXXXXX XXXXXX, XXXXX XXXXXX, XXXXXXXXX XXXXXX XX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX. XXXXXX XXXXXXX XXX X.X. XXX XXXXXXXXXXX XXXXXXXX XX XXXXXXX XXXXXXXXXXX XX XXXXXXX XXX XXXXXX. XX XXXXX XXXXXXXXXX, XXXXXXX XXXXXXXXXX XXX XXXX XXXXXXXXX XXXX XXX XXXXXX XXXXXX XX XX XXX XXXXXXXXX XX XXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXX XXXX-XXXX XX XXXX, XXXXXXXXX XXXXXXX XXXXX XXXXXXXXX X XXXXXXX XX $X.XXX XXXXXXX. XXXXXXX XXXXX XXXXXXX XXX X.X. XXXX $X.XXX XXXXXXX, X X XXXXXXX XXXXXXXX XXXXXX XX XXXXX XXXXXX XXX XXXXXXXXX XXXXXXX XXXXXX, XXXXXXXXX XXXXXX XX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XX XXXXXXXX, XXX XXX XXXXXXXX XXXXXXXX XXX XXX XXXXXXXXXXX XXXXXXXXX XX XXXXX XXXXXXXXXX XXXXXXXX XX XXXXXX. XX XXXXXXXX, XXX XXX XXXXXXXX XXXXXXXX XXX XXX XXXXXXXXX XX XXXXXXXXXXX XXXXXXX XXXXXXXX. XXXXXX XXXX, XX XXXXXXXXX X XXXXXXXXXXXX XXX XXXX XXXXXXXXXXX XX XXX XXX XXX XXXXXXXX XXX XXX XXXXXXXXXX XX XXXXXXXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXX XX XXXXXXXX, X XXXXXXX XXX XXX XXXXXXXXX XX XXXXX XXXXXXXXXX XXXXXXXX, XXXXXXXX XXXXXXXXXX XXXXXXXXXXX XXXX, XXX XXXXXXXXXXX XXXXXXX XXXXXXXX, XXXXXXXXX XX XXXXXXX XX XXX X.X., XXXXXX XXXXXXXXX XX XXXXXX XXXXXX. XXXXX XXXXXXX XXX X.X. XXXXXXXXX XX XXXXXXX, XXXXXX XX XXXXXXXXX XXXXXX XXX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXX XXXX XXXX XX XXXX, XXXXXXXXX XXXXXXXX XXXXX XXXXXXXXX XX XXXXXXX, XX $X.XXX XXXXXXX. X.X. XXXXXXXX XXXXX XXX XXXX XXXX $X.XXX XXXXXXX, X XX XXXXXXX XXXXXXXX XXXXXX XXXXXXXXX XX XXXXXX XXXXXX. XXXXXXXX XXXXX XXXXXXX XXX X.X. XXXX $XXX.X XXXXXXX, X XX XXXXXXX XXXXXXXX, XXXXXX XX XXXXXXXXX XXXXXX XXX XXXXXXXXX XXXXXXXX XXXXX.

XXXXXX: XXXXX XXXXXXX (XX XXX XXXX):
XXX XXXXX XXX XXXXXXX XXXXXXXXX XXXXX XXXX XXX X.X. XXXX XXX XXXX XXXXXXXXXXXXXX (XXX) XXX XXXXXXXX XXXXXXXX® (XXXXXXXXXX XXX) XXX XXX XXXXXXXXXXX XXXXXXXXX XX XXXXX XXXXXXXXXX XXXXXXXX (XXX) XX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX, XX:
XXXXXXXX XXXXX XX $X.XX XXXXXXX XXXXXXXXXXX XX XXXXXXX XX XXX XXXX XXXXXXXX. XXX XXXXX XXXXXXXX.

XXXX XX:
XXXXX XX XXXXXXXX, X XXXXXXX XXX XXX XXXXXXXXX XX XXXXX XXXXXXXXXX XXXXXXXX, XXXXXXXX XXXXXXXXXX XXXXXXXXXXX XXXX, XXXXXXXXXXX XXXXXXX XXXXXXXX, XXX XXXXXXXXXXXX, XXXXXXXXX XX XXXXXXX XX XXX X.X., XXXXXX XX XXXXXXXXX XXXXXX XXX, XX X XXXXXX XXXXXX, XXXXXX XXXXXX. XXXXX XXXXXXX XXX X.X. XXXXXXXXX XX XXXXXXX, XXXXXX XX XXXXXXXXX XXXXXX XXX, XX X XXXXXX XXXXXX, XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX XXX XXXXXX XXXXXX. XXXXXX XXXXXX XXXXXXX XXX X.X. XXXXXXXX XXXXXXXXX XXXXXX XX XXXXXXXXXXX XXXXXXX XX XXXX XX XXXXXX XXXXXXXX XX XXX XXXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXX XXXX-XXXX XX XXXX, XXXXXXXXX XXXXXXXX XXXXX XXXXXXXXX XX XXXXXXX XX $X.XXX XXXXXXX. XXXXXXXX XXXXX XXXXXXX XXX X.X. XXXX $XXX.X XXXXXXX, X XX XXXXXXX XXXXXXXX XXXXXX XX XXXXXXXXX XXXXXX XXX XX X XXXXXX XXXXXX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX XXX XXXXXXXXX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXX XX XXXXXXX, XXX XXXXXXXXXX XXXXX XXXXXXX XXXXXX XXX XXX XXXXXXXXX XX XXXXXXXX, XXXXXXXXX X XXXXXXX XX XXX X.X., XXXXXX XX XXXXXX XXXXXX XXX XXXXXXXXX XXXXXX. XXXXX XXXXXXX XXX X.X. XXXXXXXXX XX XXXXXXX, XXXXXX XX XXXXXXXXX XXXXXX XXX XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX, XXXXXXXXX XXXXXX XX XXXXXXXXX XXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXX XXXX XXXX XX XXXX, XXXXXXXXX XXXXXXX XXXXX XXXXXXXXX XX XXXXXXX, XX $X.XXX XXXXXXX. X.X. XXXXXXX XXXXX XXX XXXX XXXX $XXX.X XXXXXXX, X X XXXXXXX XXXXXXXX XXXXXX XX XXXXXX XXXXXX XXX XXXXXXXXX XXXXXX. XXXXXXX XXXXX XXXXXXX XXX X.X. XXXX $XXX.X XXXXXXX, X XX XXXXXXX XXXXXXXX, XXXXXX XX XXXXXXXXX XXXXXX XXX XXXXXXXXX XXXXXXXX XXXXX, XXXXXX XX XXXX, XX XXXXXXXXX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXX XX XXXXXXX, XXX XXXXXXXXXX XXXXX XXXXXXX XXXXXX XXX XXX XXXXXXXXX XX XXXXXXXX, XXXXXXXXX XX XXXXXXX XX XXX X.X., XXXXXX XX XXXXXXXXX XXXXXX XXX XXXXXX XXXXXX. XXXXX XXXXXXX XXX X.X. XXXXXXXXX XX XXXXXXX, XXXXXX XX XXXXXXXXX XXXXXX XXX, XX X XXXXXX XXXXXX, XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXX XXXX-XXXX XX XXXX, XXXXXXXXX XXXXXXX XXXXX XXXXXXXXX XX XXXXXXX XX $X.XXX XXXXXXX. XXXXXXX XXXXX XXXXXXX XXX X.X. XXXX $XXX.X XXXXXXX, X XX XXXXXXX XXXXXXXX XXXXXX XX XXXXXXXXX XXXXXX XXX, XX X XXXXXX XXXXXX, XXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXX XXXXX.

Company Specific NameCardiovascular less sales of Reopro & Xigris

XXXXXXXX XX $X:
X) +XXXX.X XXXXXXXXXXXXXX (XXXXXX: XX XXXX XXXXXXXXXXX XXXXXXX).

XXXXX

X) XXXXXX XXXXX
(XXX XXXXX XXXXXXXX XXX XXXXX XX XXXXXX XX XXXXXXXXXXXXXX, XXX XX XXXXXXXX XXXXXXXXXXXXXX, XX XX XXXXXXX XX 'XXXXXX XXXXXXXXXXX' XX XXXXXX-XXXXXXX. XXXXXXXXX, XXX XXXXX XX XXXXXX XXXX XXXX XXXXX XXX XX XXX XXXXX XXXXXXXXXXXXXX XXXXX XXXXX XX XXX XXXXXXX XX XXX XXXXXX XXXXXX).

X) XXXXXX XXXXX
(XXX XXXXX XXXXXXXX XXX XXXXX XX XXXXXX XX XXXXXXXXXXXXXX, XXX XX XXXXXXXX XXXXXXXXXXXXXX, XX XX XXXXXXX XX X 'XXXXXXXX XXXXXXXXXXX XXXXXXXXX' XX XXXXX. XXXXXXXXX, XXX XXXXX XX XXXXXX XXXX XXXX XXXXX XXX XX XXX XXXXX XXXXXXXXXXXXXX XXXXX XXXXX XX XXX XXXXXXX XX XXX XXXXXX XXXXXX).

X) XXXXXX XXXXX
(XXX XXXXX XXXXXXXX XXX XXXXX XX XXXXXX XX XXXXXXXXXXXXXX, XXX XX XXXXXXXX XXXXXXXXXXXXXX, XX XX XXXXXXX XX X 'XXXX-XXXXXXXXX' XX XXXXX. XXXXXXXXX, XXX XXXXX XX XXXXXX XXXX XXXX XXXXX XXX XX XXX XXXXX XXXXXXXXXXXXXX XXXXX XXXXX XX XXX XXXXXXX XX XXX XXXXXX XXXXXX).

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NameNeurosciences

XXXXXXXX XX $X:
X) +XXXXX.X XXXXX XXXXXXXXXXXXXXX.

XXXXX
X) +XXX.X XXXXXXX XXXXXXX XXXX XXXXX XX XXXX.
X) +XXX.X XXXXXX XX% XXXXX XXXXXX XXXXX XX XX XXXXX XXXX XXXXXX XX XXXX.

XXXXXXXX XX $X:
X) +XXXX.X XXXXXXXXXXXXX XXXXX.
XXXXX:
X) +XX.X XXXXXXXXX XXXXXXXX (XXXXXXXXXX XX XXX XXXXX XX XXXXXXXXXXXX & XX XXXXXXXXXXXXXX XX XXXXXX-XXXXXXX).
X) -X.X XXXXXXXXX XXX.

XXXXXX: XX XXXX XXXXXXXXXXX XXXXXXX.

XXXXXXXX XX $X:
X) +XXXXX.X XXXXX XXXXXXXXXXXXXXX.

XXXXX
X) +XXXX XXXXXX XXXXXXXXXX.
X) +XXX.XX XXXXXX XX% XXXXX XXXXXX XXXXX XX XX XXXXX XXXX XXXXXX XX XXXX.

Company Specific NameEndocrinology

XXXXXXXX $X:
X) +XXXX.X XXXXXXXXXXXXX (XXXXXX: XX XXXX XXXXXXX).

XXXXX
X) +XXXX.X XXXXXX (XXXXXXXXXX XX XXXXXXXX XX 'XXXX XXXXXXX XXXXXXXXX' XXXXXX XXXXXXXXXXXXXXX, XXXXXXXXX XXXXXXX XXXX XXX'X XXXXXXXXXXXXX XXXXX).
X) +XXX.X XXXXXX (XXXXXXXXXX XX XXXXXXXX XX 'XXXX XXXXXXX XXXXXXXXX' XXXXXX XXXXXXXXXXXXXXX, XXXXXXXXX XXXXXXX XXXX XXX'X XXXXXXXXXXXXX XXXXX).
X) +XX.X XXXXXX (XXX XXXXXXXX XXXXXXX).
X) +XXX.X XXXXX XXXXXXXX.

XXXX:
X) XXXXX XXXXXXXX XX% XXXXX XX XXXXX XXXXXX XX XX XXXXX XX XXXXXX XXXX XXXXXX + XXXXXXX XXXX XXXX XX XXXXXX XXX XXXXXXXX XXXXXXX XX XXXXXX.
X) XXXXXX XXXX XXX XX% XX XXXXX XXXXXXX & X XXX XXXXX XXX XXX XX-XXXXXXXXX XXXXX XX XX. XXX XXXXX XXXXXXX XXXX XXXXXXX XX XXXXXXXXX XXXXX, XXXXXXX XX XXXXXXX XX XXXXXXXX XXX XXXXXXXX XX XXXXX XXXXXXXXXXXXXXX/XXXXX XXXXXXXXXXX/XXXXXXXX XXXXXXXX.

Company Specific NamePrimary Care

Company Specific NameOncology

XXXXXXXX XX $X:
X) +XXXX.X XXXXXXXX XXXXX.
XXXX:
X) +X.X XXXXXXX XXXXXXXXXXXXX XXXXXXX.
XXXXXX: XX XXXX XXXXXXX.

Company Specific NameAnti-infectives

XXXXXXXX XX $X:
X) +XXX.X XXXX-XXXXXXXXXX XXXXX.

XXXXXX: XX XXXX XXXXXXX.